IMEIK

BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious

BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.

Noah Hospital Logistics Robot Received over Ten Million CNY in Series B+ Round

Noah Hospital Logistics Robot recently received over ten million CNY in Series B+ round, with most of the funds going toward product development and marketing.

AI-driven Biotech Galixir Nominates Preclinical Candidate in Treating Autoimmune Disease

Founded in 2019, Galixir named a Preclinical Candidate (PCC) for the treatment of Autoimmune Disease (AID) which was screened out of around 80 compounds via its proprietary platform, Pyxir®, making it another top-ranking China-based AI-driven drug discovery company.

Where Will AI Take Drug Discovery in China to?

The development of drug discovery in China is relatively slower than in many other countries but China’s pharma market size is among the top three worldwide. Deeper exploration of drug discovery is much needed in China. AI can make a machine execute tasks like a human or even better than humans. With many emerging AI-powered drug discovery companies in China, can AI help China beat the pioneers in drug discovery at their own game?

ArtechMed Completes Nearly 100 Million CNY in Series C Round

ArtechMed has completed its Series C funding round, which totaled nearly 100 million CNY. 张科禾润基金 led this round of funding, which is followed by 黄埔医药基金 and Sunland Fund. Follow-up investments were also made by Dingxin Capital.